daraxonrasib

DRUG13 trials

Sponsors

Revolution Medicines, Inc., Bristol-Myers Squibb, ParVation Therapeutics, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Children's Oncology Group

Conditions

Advanced Solid TumorsAmpulla of Vater CarcinomaAmpullary CarcinomaBiliary Tract CancersCRCColorectal CancerColorectal Cancer (CRC)Extrahepatic Cholangiocarcinoma

Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RecruitingNCT06128551

Revolution Medicines, Inc.Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma

Start: 2023-11-14End: 2029-06-01Target: 534Updated: 2026-09-22

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

RecruitingNCT07349537

Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +7

Start: 2026-01-08End: 2028-10-01Target: 574Updated: 2026-09-17

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

RecruitingNCT07397338

Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +3

Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-08-03

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

RecruitingNCT07756281

ParVation Therapeutics, Inc.Pancreatic Acinar Carcinoma, Pancreatic Cancer

Start: 2026-09-01End: 2029-06-01Target: 40Updated: 2026-10-27

Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

Not yet recruitingNCT07819838

Children's Oncology GroupRecurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma +3

Start: 2027-04-09End: 2032-04-09Target: 77Updated: 2026-09-15

Daraxonrasib in Resectable PDAC

Not yet recruitingNCT07898813

Dana-Farber Cancer InstitutePancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma

Start: 2027-04-13End: 2029-08-13Target: 30Updated: 2026-10-27

Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

RecruitingNCT07492680

Bristol-Myers SquibbSolid Tumors

Start: 2026-07-27End: 2032-05-20Target: 260Updated: 2026-10-06

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Not yet recruitingNCT07793253

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAmpulla of Vater Carcinoma, Ampullary Carcinoma, Biliary Tract Cancers +3

Start: 2026-11-01End: 2030-11-01Target: 55Updated: 2026-08-28

Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

RecruitingNCT06881784

Revolution Medicines, Inc.Non-Small Cell Lung Cancer, NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) +2

Start: 2025-05-06End: 2030-12-01Target: 590Updated: 2026-09-29

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingNCT07252232

Revolution Medicines, Inc.Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma +2

Start: 2025-12-15End: 2030-07-10Target: 500Updated: 2026-10-23

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07491445

Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5

Start: 2026-03-09End: 2029-03-01Target: 900Updated: 2026-10-02

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

RecruitingNCT07805954

Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5

Start: 2026-08-28End: 2030-04-01Target: 400Updated: 2026-10-16

Unknown Phase

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Revolution Medicines, Inc.Metastatic Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic +5

Updated: 2026-09-01

Related Papers

Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Cancer Research2026-04-17

Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcoma

Cancer Research2026-03-05

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

Journal of Medicinal Chemistry2025-03-0832 citations

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

Journal of Medicinal Chemistry2025-02-2422 citations